These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 8186809)

  • 1. Fluoxetine: a randomized clinical trial in the treatment of obesity.
    Goldstein DJ; Rampey AH; Enas GG; Potvin JH; Fludzinski LA; Levine LR
    Int J Obes Relat Metab Disord; 1994 Mar; 18(3):129-35. PubMed ID: 8186809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluoxetine: a randomized clinical trial in the maintenance of weight loss.
    Goldstein DJ; Rampey AH; Dornseif BE; Levine LR; Potvin JH; Fludzinski LA
    Obes Res; 1993 Mar; 1(2):92-8. PubMed ID: 16350565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analyses of suicidality in double-blind, placebo-controlled trials of pharmacotherapy for weight reduction.
    Goldstein DJ; Rampey AH; Potvin JH; Masica DN; Beasley CM
    J Clin Psychiatry; 1993 Aug; 54(8):309-16. PubMed ID: 8253699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluoxetine's effect on weight loss in obese subjects.
    Darga LL; Carroll-Michals L; Botsford SJ; Lucas CP
    Am J Clin Nutr; 1991 Aug; 54(2):321-5. PubMed ID: 1858696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of fluoxetine on body weight, body composition and visceral fat accumulation.
    Visser M; Seidell JC; Koppeschaar HP; Smits P
    Int J Obes Relat Metab Disord; 1993 May; 17(5):247-53. PubMed ID: 8389333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study (with a commentary by Michael Weintraub).
    Levine LR; Enas GG; Thompson WL; Byyny RL; Dauer AD; Kirby RW; Kreindler TG; Levy B; Lucas CP; McIlwain HH
    Int J Obes; 1989; 13(5):635-45. PubMed ID: 2583918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
    McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K;
    J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An open-label pilot study of the combination therapy of metformin and fluoxetine for weight reduction.
    Dastjerdi MS; Kazemi F; Najafian A; Mohammady M; Aminorroaya A; Amini M
    Int J Obes (Lond); 2007 Apr; 31(4):713-7. PubMed ID: 16969361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study.
    Muls E; Kolanowski J; Scheen A; Van Gaal L;
    Int J Obes Relat Metab Disord; 2001 Nov; 25(11):1713-21. PubMed ID: 11753595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
    Sánchez-Reyes L; Fanghänel G; Yamamoto J; Martínez-Rivas L; Campos-Franco E; Berber A
    Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An assessment of the thermogenic effects of fluoxetine in obese subjects.
    Stinson JC; Murphy CM; Andrews JF; Tomkin GH
    Int J Obes Relat Metab Disord; 1992 May; 16(5):391-5. PubMed ID: 1319975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of serotonin re-uptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity.
    Pijl H; Koppeschaar HP; Willekens FL; Op de Kamp I; Veldhuis HD; Meinders AE
    Int J Obes; 1991 Mar; 15(3):237-42. PubMed ID: 1646182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
    Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR
    J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients.
    Kopelman P; Bryson A; Hickling R; Rissanen A; Rossner S; Toubro S; Valensi P
    Int J Obes (Lond); 2007 Mar; 31(3):494-9. PubMed ID: 16953261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity.
    Bray GA; Hollander P; Klein S; Kushner R; Levy B; Fitchet M; Perry BH
    Obes Res; 2003 Jun; 11(6):722-33. PubMed ID: 12805393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity.
    Levine LR; Rosenblatt S; Bosomworth J
    Int J Obes; 1987; 11 Suppl 3():185-90. PubMed ID: 3501994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuation treatment of OCD: double-blind and open-label experience with fluoxetine.
    Tollefson GD; Birkett M; Koran L; Genduso L
    J Clin Psychiatry; 1994 Oct; 55 Suppl():69-76; discussion 77-8. PubMed ID: 7961535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population.
    Cuellar GE; Ruiz AM; Monsalve MC; Berber A
    Obes Res; 2000 Jan; 8(1):71-82. PubMed ID: 10678261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double-blind, placebo-controlled trial of fluoxetine plus behavior modification in the treatment of obese binge-eaters and non-binge-eaters.
    Marcus MD; Wing RR; Ewing L; Kern E; McDermott M; Gooding W
    Am J Psychiatry; 1990 Jul; 147(7):876-81. PubMed ID: 2192563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial.
    García-Morales LM; Berber A; Macias-Lara CC; Lucio-Ortiz C; Del-Rio-Navarro BE; Dorantes-Alvárez LM
    Clin Ther; 2006 May; 28(5):770-82. PubMed ID: 16861099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.